Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Dec 17;10(1):e016696. doi: 10.1161/JAHA.120.016696

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

(A) Coronal single‐photon emission computed tomography/x‐ray computed tomography scV/Tc scans from a pig treated with IgG on left and pig treated with anti–receptor for advanced glycation end products antibody (CR‐3) on the right. The yellow arrow points to the occluder. The red line outlines the gastrocnemius muscle. The green arrow points to the greater uptake of scV/Tc in gastrocnemius in the CR‐3 treated pig compared with IgG treated pig. (B) Bars represent mean±SD for ratios of percentage injected dose (%ID) of uptake of scV/Tc for the IgG treated pigs (orange bar) and CR‐3 treated pigs (gray bar). (C) Lectin staining for capillaries shows more abundant capillaries in CR‐3 treated (right) compared with IgG (left). (D) Bars represent mean±SD quantitative lectin staining. (E) Immunostaining for vascular endothelial growth factor A (VEGFA) showing greater capillary staining in muscle from CR‐3 treated pigs. (F) Bars represent mean±SD for quantitative VEGFA staining.